GlassScriptPhysician profile
Matthew S Kaatz
NPI 1255394557
$12,611.72
in general payments reported to CMS, 2019-2025
50 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,395 · 2020: $1,972 · 2021: $3,099 · 2022: $2,669 · 2023: $849 · 2024: $402 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,478.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,339.78 | 2019-2024 | Farxiga, Breztri |
| Novo Nordisk INC | $1,072.44 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $946.15 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $933.60 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $931.81 | 2019-2024 | |
| Abbott Laboratories | $608.03 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $589.09 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $532.89 | 2019-2024 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $509.45 | 2019-2022 | |
| Pfizer INC. | $472.72 | 2019-2025 | |
| Allergan, INC. | $429.86 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $369.69 | 2019-2025 | Xifaxan |
| Dexcom, INC. | $308.50 | 2021-2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $280.41 | 2019-2023 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $252.07 | 2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Kaatz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.